Particles for use in hyperpolarization
Described herein are particles comprising a crystalline matrix and a dopant, wherein one of the atoms of the matrix is 19 F and 31 P, or 13 C, 15 N, 29 Si, 16 O, 17 O, 23 Na, 39 K, 25 Mg, 40 Ca, 43 Ca or deuterium; and the dopant is a compound involved in a biological process in a mammalian organism; and wherein the dopant is present in an amount of between 0.01% and 20% of the plurality of particles, and wherein when the matrix comprises an atom selected from the group of 13 C, 15 N, 29 Si, 16 Q, 17 O, 23 Na, 39 K, 25 Mg, 40 Ca, 43 Ca and deuterium, and the dopant is isotopically enriched.
1. A method for preparing an imaging probe comprising, obtaining a plurality of particles comprising a crystalline matrix and a dopant, wherein the matrix is present in an amount of between 80% and 99.99% of the plurality of particles by weight, and the matrix is a crystalline salt comprising an ion selected from the group consisting of: CO 3 −2 , HCO 3 − , C 2 O 4 , PO 4 , HPO 4 , H 2 PO 4 , OH − , NO 3 , and NO 2 wherein at least one of the atoms of the matrix is selected from the group consisting of:
13 C 15 N, 29 Si, 16 O, 17 O, 23 Na, 39 K, 25 Mg, 40 Ca, 43 Ca and deuterium; and
the dopant is isotopically enriched with the same atom,
and the dopant is a compound involved in a biological process in a mammalian organism selected from the group consisting of: an amino acid, a monosaccharide, a disaccharide, a choline, a nucleobase, a carboxylic acid, or a biological waste product, a metabolite, a neurotransmitter, a peptide, a vitamin, a pharmaceutical agent, a hormone, a psychoactive agent, an alcohol, a glycol, glycerine, a fatty acid, a phospholipid, a lecithin, or cholesterol; and wherein the dopant is present in an amount of between 0.01% and 20% of the plurality of particles by weight, and the dopant acts as the imaging probe;
wherein the particles have a water solubility of between 1×10 −5 M and 6 M at room temperature; and wherein the dopant is uniformly dispersed within the particles;
and polarizing the plurality of particles.
2. The method according to claim 1 , wherein polarizing the plurality of compounds comprises hyperpolarization.
3. The method according to claim 1 , wherein the matrix and the dopant are each isotopically enriched with at least an atom selected from the group consisting of: 13 C, 15 N, 29 Si, 17 O, or deuterium.
4. The method according to claim 1 wherein the salt is selected from the group consisting of: CaCO 3 , Na 2 CO 3 , K 2 CO 3 , NaHCO 3 , KHCO 3 , LiHCO 3 , NH 4 HCO 3 , MgCO 3 , CaC 2 O 4 , Na 2 C 2 O 4 , K 2 C 2 O 4 , Li 3 PO 4 , Na 3 PO 4 , K 3 PO 4 , (NH 4 ) 3 PO 4 , Ca 3 (PO 4 ) 2 , Mg 3 (PO 4 ) 2 , Ca(H 2 PO 4 ) 2 , CaHPO 4 , Ca 5 (PO 4 ) 3 (OH), Ca 10 (PO 4 ) 6 (OH) 2 , Ca 10 (PO 4 ) 6 F 2 , Ca 10 (PO 4 ) 6 C 12 , and Ca 10 (PO 4 ) 6 Br 2 .
5. The method according to claim 4 wherein the salt is selected from the group consisting of: CaCO 3 , Na 2 CO 3 , K 2 CO 3 , and MgCO 3 and wherein the carbonate ion and the dopant are isotopically enriched with 13 C.
6. The method according to claim 1 , wherein the amount of dopant is between 0.5% and 10% by weight.
7. The method according to claim 6 , wherein the amount of dopant is between 1% and 10% by weight.
8. The method according to claim 1 wherein the dopant is an amino acid, or pyruvate.
9. The method according to claim 1 wherein, the mean particle size is between 50 and 500 nanometers.
10. The method according to claim 1 wherein under ambient conditions and a magnetic field in the range of from 0.5 tesla (0.5 T) to 20 T, the matrix has a substantially long spin-lattice relaxation time (T 1 ), between 30 seconds to 1 hour.
11. The method according to claim 8 wherein the dopant is glycine.
12. The method according to claim 1 wherein upon polarization, magnetization is conducted from the matrix to the dopant.
13. The method according to claim 1 , further comprising administering the imaging probe to a patient in need thereof, and performing an imaging procedure on the patient.
14. The method according to claim 13 , wherein the imaging procedure is magnetic resonance imaging.